BIO Conference Upcoming Lecture" "The Case for Naming Sooner ...Than Later"
Bill Smith, CEO of Brand Acumen.
The global leader in pharmaceutical name development and submissions.
CAR-T (Cell Therapy) Nomenclature Review & Brand Equity Study. April 15, 2015Bill Smith
CAR-T (Cell Therapy) Nomenclature Review & Brand Equity Study. April 15, 2015.
Brand Acumen. The Global Leader in Pharmaceutical Name Development and Submission Strategy.
CAR-T (Cell Therapy) Nomenclature Review & Brand Equity Study. April 15, 2015Bill Smith
CAR-T (Cell Therapy) Nomenclature Review & Brand Equity Study. April 15, 2015.
Brand Acumen. The Global Leader in Pharmaceutical Name Development and Submission Strategy.
Myriad genetics, inc. product pipeline analysisraja1233
Companyprofilesandconferences.com glad to promote a new report on "Myriad Genetics, Inc. (MYGN) - Product Pipeline Analysis" which is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products who provides key information about the company, its major products and brands.
Performing Competitive Intelligence in a Pharmaceutical CompanyAnthony Russell
Workshop presented in the Competitive Intelligence and Pricing course as part of the University of Southern California Master of Science in Healthcare Decision Analysis program. Presented on Nov 4, 2018 at USC. The workshop gives an overview of what competitive intelligence is and how it is done in pharmaceutical companies. The workshop includes a couple of non-pharmaceutical exercises to help students learn how to write key intelligence questions and to work through a market simulation exercise. The workshop ends with a discussion on the various career pathways available within the competitive intelligence field.
How to Work Effectively with Research Teams in New Product PlanningAnthony Russell
Presented at the 3rd New Product Planning Summit. The presentation was designed to help professionals in New Product Planning to present a case for why commercial strategy input is needed early in the process of developing new therapeutics. The presentation also includes suggested approaches and tools to help with effective engagement with Research teams.
Building a Business Case for New Product Planning in a Small Company EnvironmentAnthony Russell
Presented at the 2nd New Product Planning Summit by ExL Events in Boston (Dec 8, 2017). An overview of why commercial strategy is needed early in product development. As pressures continue to mount in drug development (crowded markets, payer and access issues, etc.), it is becoming critical to focus on the early stages of drug development. Working early with research and development teams to evaluate the commercial viability of programs will benefit companies of all sizes to maximize their portfolio of therapeutic candidates.
How and When to Kill a Program in New Product PlanningAnthony Russell
Presented at the 4th New Product Planning Summit in Boston (Dec 2 -3 , 2019). Presentation covers why weak programs should be cut from pharmaceutical and biotech pipelines, what defines a "weak" program, and describes objective methods to evaluate programs to help prioritize assets.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This new 900-page five-country market intelligence and technology assessment report from Venture Planning Group will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in major European countries (France, Germany, Italy, Spain, UK); provides estimates of the specimen, test and sales volumes, as well as major suppliers sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. However, this evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
Making Key Decisions in New Product Planning When “Perfect” Information is No...Anthony Russell
Presentation given at New Product Planning Summit 2021.
Learning Objectives:
* Review the types of decisions typically made in New Product Planning
* Discuss the nature of information available to support decision-making in New Product Planning
* Review the impact and context of decision-making in New Product Planning
* Review potential approaches to assist in New Product Planning decision-making
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
Speakers:
Paul Chipperton, Vice President, Business Development & Marketing, matREGEN
Nina Chagnon, Director of Business Development, MaRS Discovery District
For more information and the webcast link: http://www.marsdd.com/Events/Event-Calendar/BioEntrepreneurship/2007/business-models-12192007.html
Myriad genetics, inc. product pipeline analysisraja1233
Companyprofilesandconferences.com glad to promote a new report on "Myriad Genetics, Inc. (MYGN) - Product Pipeline Analysis" which is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products who provides key information about the company, its major products and brands.
Performing Competitive Intelligence in a Pharmaceutical CompanyAnthony Russell
Workshop presented in the Competitive Intelligence and Pricing course as part of the University of Southern California Master of Science in Healthcare Decision Analysis program. Presented on Nov 4, 2018 at USC. The workshop gives an overview of what competitive intelligence is and how it is done in pharmaceutical companies. The workshop includes a couple of non-pharmaceutical exercises to help students learn how to write key intelligence questions and to work through a market simulation exercise. The workshop ends with a discussion on the various career pathways available within the competitive intelligence field.
How to Work Effectively with Research Teams in New Product PlanningAnthony Russell
Presented at the 3rd New Product Planning Summit. The presentation was designed to help professionals in New Product Planning to present a case for why commercial strategy input is needed early in the process of developing new therapeutics. The presentation also includes suggested approaches and tools to help with effective engagement with Research teams.
Building a Business Case for New Product Planning in a Small Company EnvironmentAnthony Russell
Presented at the 2nd New Product Planning Summit by ExL Events in Boston (Dec 8, 2017). An overview of why commercial strategy is needed early in product development. As pressures continue to mount in drug development (crowded markets, payer and access issues, etc.), it is becoming critical to focus on the early stages of drug development. Working early with research and development teams to evaluate the commercial viability of programs will benefit companies of all sizes to maximize their portfolio of therapeutic candidates.
How and When to Kill a Program in New Product PlanningAnthony Russell
Presented at the 4th New Product Planning Summit in Boston (Dec 2 -3 , 2019). Presentation covers why weak programs should be cut from pharmaceutical and biotech pipelines, what defines a "weak" program, and describes objective methods to evaluate programs to help prioritize assets.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This new 900-page five-country market intelligence and technology assessment report from Venture Planning Group will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in major European countries (France, Germany, Italy, Spain, UK); provides estimates of the specimen, test and sales volumes, as well as major suppliers sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. However, this evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
Making Key Decisions in New Product Planning When “Perfect” Information is No...Anthony Russell
Presentation given at New Product Planning Summit 2021.
Learning Objectives:
* Review the types of decisions typically made in New Product Planning
* Discuss the nature of information available to support decision-making in New Product Planning
* Review the impact and context of decision-making in New Product Planning
* Review potential approaches to assist in New Product Planning decision-making
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
Speakers:
Paul Chipperton, Vice President, Business Development & Marketing, matREGEN
Nina Chagnon, Director of Business Development, MaRS Discovery District
For more information and the webcast link: http://www.marsdd.com/Events/Event-Calendar/BioEntrepreneurship/2007/business-models-12192007.html
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Yavuz Silay
Strategies for Conducting New Product Scientific Assessment - Due Diligence - New Strategies for Successful Licensing Acquisitions , DIA , Session Panel, June 22 2008,
The Value of Conducting Post-Marketing Clinical Research On Marketing Strategy Development
Nutraceutical Medical Research, LLC
By: Latesha Richards, Marketing Coordinator
How does the licensing process differ for in-licensing and out-licensing comp...daisyrmuzzio
PHARMA & BIOTECH LICENSING & PARTNERING:
Filling the Pipeline & Growing Market Share Through Strategic Deal-Making-- March 2-3- San Diego California
The Entrepreneur's Guide to Hospital Partnerships by @Rock_HealthRock Health
A living document and initial guide for entrepreneurs as they navigate partnering with health providers, initially compiled after 22 interviews with entrepreneurs, hospital administrators, investors, lawyers, clinicians and researchers. Purchase the report here: https://gumroad.com/l/qgUT
Prescription for Growth: Embrace a NicheRolandJacobs1
Roland Jacobs is CEO of marketing strategy firm AspireUp
Tim Calkins is a clinical professor of marketing, including biomedical marketing, at the Kellogg School of Management at Northwestern
Early asset development and commercialization: Partnering for successCello Health
To be successful in developing an asset you have to identify the need and define the commercial value early on in the development process, as well as revisiting and refining the value as you progress through the phases of development. This means understanding what else is coming onto the market from a competitive perspective and the clinical relevance from a patient perspective. Being mindful about value throughout development is also important because, at each phase more investment will be needed, especially in smaller companies. Often times the need for investment results in a licensing agreement or a partnership.
This is a follow up webinar to "The value of early asset development and commercialization." The slides take a deep dive into how to find the right partner for developing and commercializing your asset.
Guide to Online International Non-Proprietary Name (INN) Electronic Name Subm...Bill Smith
Brand Acumen's Guide to Online International Non-Proprietary Name (INN) Electronic Name Submission Process.
Brand Acumen. The Global Leader in Pharmaceutical Name Development and Submission Strategy.
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdfthesiliconleaders
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
buy old yahoo accounts buy yahoo accountsSusan Laney
As a business owner, I understand the importance of having a strong online presence and leveraging various digital platforms to reach and engage with your target audience. One often overlooked yet highly valuable asset in this regard is the humble Yahoo account. While many may perceive Yahoo as a relic of the past, the truth is that these accounts still hold immense potential for businesses of all sizes.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
An introduction to the cryptocurrency investment platform Binance Savings.Any kyc Account
Learn how to use Binance Savings to expand your bitcoin holdings. Discover how to maximize your earnings on one of the most reliable cryptocurrency exchange platforms, as well as how to earn interest on your cryptocurrency holdings and the various savings choices available.
Building Your Employer Brand with Social MediaLuanWise
Presented at The Global HR Summit, 6th June 2024
In this keynote, Luan Wise will provide invaluable insights to elevate your employer brand on social media platforms including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok. You'll learn how compelling content can authentically showcase your company culture, values, and employee experiences to support your talent acquisition and retention objectives. Additionally, you'll understand the power of employee advocacy to amplify reach and engagement – helping to position your organization as an employer of choice in today's competitive talent landscape.
Recruiting in the Digital Age: A Social Media MasterclassLuanWise
In this masterclass, presented at the Global HR Summit on 5th June 2024, Luan Wise explored the essential features of social media platforms that support talent acquisition, including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok.
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
In the Adani-Hindenburg case, what is SEBI investigating.pptxAdani case
Adani SEBI investigation revealed that the latter had sought information from five foreign jurisdictions concerning the holdings of the firm’s foreign portfolio investors (FPIs) in relation to the alleged violations of the MPS Regulations. Nevertheless, the economic interest of the twelve FPIs based in tax haven jurisdictions still needs to be determined. The Adani Group firms classed these FPIs as public shareholders. According to Hindenburg, FPIs were used to get around regulatory standards.
Authentically Social by Corey Perlman - EO Puerto Rico
BIO Conference Upcoming Lecture" "The Case for Naming Sooner ...Than Later"
1. The Case For Naming Sooner
…Than Later
April 15, 2015
Draft Presentation for BIO, 2015
Bill Smith, CEO
Brand Acumen, LLC
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
2. chimeric antigen receptor therapy
In March, 2015, a study of 79 pharmaceutical
naming and trademark professionals was
conducted by BrandAcumen.
The purpose of the study was to define
challenges and trends in the drug naming
process.
The key findings …
The Research:
Pharmaceutical Naming Impact Study
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
3. chimeric antigen receptor therapy
Drug companies are developing trademarks for
new products at an earlier stage of development
in an effort to entrench a brand in the minds of
HCPs, BioJournalists, Potential Patients,Affinity
Proponents,Academia and the Financial
Community.
The Research:
Pharmaceutical Naming Impact Study
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
4. chimeric antigen receptor therapy
The overwhelming majority of the
professionals surveyed in the study stated
that they develop generic and trademark
names, 91% and 87% respectively, before
or during Phase II of clinical trials.
The Research:
Pharmaceutical Naming Impact Study
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
5. chimeric antigen receptor therapy
The outcome of the study recommends
seeking a trademark early — even during
Phase I — as trademark searches have a
low success rate.
This fast movement is even more important
for compounds with Expedited FDAReview
Programs, Oncology, Orphan Drug, Cell and
Gene Therapy Submissions.
The Research:
Pharmaceutical Naming Impact Study
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
6. chimeric antigen receptor therapy
Moreover, the study suggests drug companies
identify empty vessel names along with
suggestive names, arguing that empty-vessel
names can be easy to identify, protect and
re-use.
In addition, they pose less of a risk for rejection
under medical error recognition evaluation or
for conflicting with clinical trials results.
The Research:
Pharmaceutical Naming Impact Study
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
7. The Survey Overview
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
8. U.S.External TM Counsel (12)
U.S. Internal (Company) TM Counsel (17)
Chief Medical Officer (9)
Regulatory (Internal) (14)
Regulatory (Government) International (7)
Commercialization/Launch Directors (20)
Sample Profile Of Survey Respondents
Total Respondents
79
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
9. U.S.External TM Counsel (12)
U.S. Internal (Company) TM Counsel (17)
Chief Medical Officer (9)
Regulatory (Internal) (14)
Regulatory (Government) International (7)
Commercialization/Launch Directors (20)
Question:
Compared to this time last year, do you
feel compelled to begin the naming
process earlier in the drug development
cycle due to increased obstacles in
clearing a name?
10 of 12
13 of 17
6 of 9
9 of 14
4 of 7
17 of 20
TheResearchResults:
PharmaceuticalNamingImpactStudy
The ‘Yes’ Responses
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
10. U.S.External TM Counsel (12)
U.S. Internal (Company) TM Counsel (17)
Chief Medical Officer (9)
Regulatory (Internal) (14)
Regulatory (Government) International (7)
Commercialization/Launch Directors (20)
Question:
Do you believe that general costs
associated with naming have
escalated from two (2) years ago?
9 of 12
14 of 17
5 of 9
13 of 20
4 of 7
7 of 14
TheResearchResults:
PharmaceuticalNamingImpactStudy
The ‘Yes’ Responses
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
11. U.S.External TM Counsel (12)
U.S. Internal (Company) TM Counsel (17)
Chief Medical Officer (9)
Regulatory (Internal) (14)
Regulatory (Government) International (7)
Commercialization/Launch Directors (20)
Question:
Do you believe that the growing
number of FDA naming
submissions has caused a
slowdown in the review process
over the past two (2) years?
TheResearchResults:
PharmaceuticalNamingImpactStudy
The ‘Yes’ Responses
10 of 12
13 of 17
6 of 9
9 of 14
4 of 7
17 of 20
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
12. The New Factors Impacting Naming
BrandAcumen
“The Global Leader in Pharmaceutical Name Development and Submissions”
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
13. chimeric antigen receptor therapy
bioarbitrage
In the BioArbitrage Fund, the
business model acquires early stage
assets (compounds), then quickly
repackages and embellishes the
asset for divestiture.
By creating a brand name at Pre-
Clinical/ Phase I development, the
fund amplifies the ROI prior to
‘flipping the asset’ (divesting) to an
acquirer.
Identification of Asset (Pre-Clinical or Phase I)
Negotiate Terms of Option Agreement with Seller
Brand the Asset. Name, Design, Positioning, etc.
.
Create Offering Memorandum for Divestiture
Market Asset to Potential Acquirers
Close Transaction Triggering The Option
Resulting in net ‘delta’ gain (arbitrage)
BioArbitrage Process
Early Stage Naming
• Pre-Clinical
• Phase I
EmergingNewBusinessModelsareDrivingEarlyStage
NameDevelopment
thearbitrageimpact
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
14. chimeric antigen receptor therapy
An orphan drug accelerator focused on
developing and delivering life-transforming
therapies for patients with severe and life-
threatening rare diseases.
Orphanetics is privately funded by public and
private investors from the pharmaceutical, life
sciences and global healthcare community.
orphanetics
Orphanetics engages in:
• Early Stage Naming of Clinical Programs
• Non-Proprietary Name Development
• Proprietary Name Development
• EPC Naming
• New Disease Branding • MultiModal Orphan Drug Class
• Infinitive Phenoptics
• Vektür Micro Orphan Designation
• Harlequin Gan Syndrome
• Terracon SoSai Disorder
EmergingNewBusinessModelsareDrivingEarlyStage
NameDevelopment
therarediseasebio-accelerator
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
16. chimeric antigen receptor therapy
EmergingNewBusinessModelsareDrivingEarlyStage
ProprietaryNameDevelopment
The dawn of ‘Name Repositories’ which own a
broad portfolio of pharmaceutical and life
science trademarks, service marks, platform
identifiers, disease state nomenclature and
domain names is the next wave indicator of the
value of names as an intellectual property asset.
These repositories operate as IP estates with a
focus on capturing value in nomenclature as an
asset.
Emergence of Private Pharmaceutical
Name Repositiories
Structured around the concept of
Microsoft Co-Founder Nathan Myhrvold’s
Intellectual Ventures, this new breed of
‘name bank’ is creating a greater need to
capture naming assets early.
thenewbankers
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
17. chimeric antigen receptor therapy
• CAR-T
• GeneTherapy
• CRISPR
Companies benefit from early stage naming as
first to market leaders in their respective fields.
Additionally, as these companies seek strategic
partners and funding, brands become assets,
which in turn enhance valuations.
New Drug Technology Platforms
SleepingBeauty
RheoSwitch®
ZIOPHARM
platformbrands
AttSite®
UltraVector®
LEAP®
In the case of ZIOPHARM, brand recognition can also
be key to securing pivotal strategic and financial
partnerships.
investment
newplatform
earlystagebrands
EmergingNewBusinessModelsareDrivingEarlyStage
ProprietaryNameDevelopment
earlierstagenaming
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
18. EarlierNamingBehavior
18
As a result of a greater
number of sponsors
participating in the FDA’s
Expedited Review Programs,
the proliferation of name
candidate submissions has
created a strain on FDA
resources for naming reviews.
FDA’sExpeditedReviewPrograms
Breakthrough
Designation
Accelerated
Approval
Fast Track
Designation
Priority
Review
The byproduct is that
companies are
beginning the naming
process earlier to
ensure approvals
through the parallel
channels of the FDA
and PTO
moreandmorenamesubmissions
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
19. chimeric antigen receptor therapy
In the case of emerging drug discovery platforms, securing the first non-proprietary
designation can also prove beneficial as competitors may be compelled to adopt variants
of the nomenclature in their USAN filings.
tisagenlecleucel-T
tisa – gen – lec – leu – cel - T
generic name
non-proprietary name
thenon-proprietaryadvantage EmergingNewBusinessModelsareDrivingEarlyStage
Non-ProprietaryNameDevelopment AsWell
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
20. chimeric antigen receptor therapy
TheResearchResults:
PharmaceuticalNamingImpactStudy
CAR-T
anewlexicon
Next generation
technology platforms
birth entire new lexicons
overnight.
With this, one must also
consider the
implications of the entire
framework of the
healthcare ecosystem
when selecting name
candidates.
newlexicons:moreconfusion
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
21. chimeric antigen receptor therapy
Factors Driving Early Stage Proprietary Naming
• In the case of rare diseases and high profile unmet needs (liver ,
pancreatic cancers, etc.), drug companies are recognizing the
benefits of branding early to secure top of mind recognition sooner
than later.
• Compliance with FDA and PTO protocols is becoming more difficult
resulting in extended timelines.
• Aligning a “brand moniker” to a compound can protect the
corporate brand from adverse effects during clinical trials.
• FDA Naming Guidance will become more complex, not less in the
future.
keyinsights
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
22. chimeric antigen receptor therapy
Factors Driving Early Stage Proprietary Naming
• Drug companies are taking a page from the “high technology
playbook” when it comes to branding. The ‘First Mover Advantage’
is becoming more relevant as niche platforms define the importance
of being first to market. (i.e. CAR-T therapies)
• “High Science” in the case of many emerging drug platforms is
becoming relevant as a communication messaging model. (Juno,
Bluebird Bio, Spark Therapeutics)
• Trademarks are more difficult to secure. There will be less name
options available the longer one waits to secure the mark.
• Many trademark professionals are mapping out a clear parallel filing
strategy for the PTO and FDA. (see slide)
keyinsights
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”